Hennessy S, Strom B L, Berlin J A, Brennan P J
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia 19104-6095, USA.
J Gen Intern Med. 1995 Jul;10(7):380-6. doi: 10.1007/BF02599836.
To measure the incidence of cutaneous hypersensitivity reactions to cotrimoxazole in the setting of primary Pneumocystis carinii pneumonia (PCP) prophylaxis: to measure the incidence of severe reactions: and to identify predictors for these outcomes.
Retrospective cohort study.
One university-based outpatient HIV clinic and one university-affiliated internal medicine and infectious disease medical practice.
Two hundred thirty-six HIV-infected individuals receiving cotrimoxazole for primary PCP prophylaxis.
None.
Occurrence of a cutaneous hypersensitivity reaction, defined as rash, fever, or pruritus that resulted in permanent discontinuation of cotrimoxazole. Severe reactions were defined as those resulting in hospital admission or systemic treatment with a corticosteroid. Cox regression was used to calculate relative rates (RRs) and 95% confidence intervals (CIs) for a number of clinical and laboratory variables.
Forty-eight (20%) subjects developed cutaneous hypersensitivity reactions, with six (12.5%) of these being severe. In the unadjusted analysis, the following factors demonstrated at least borderline association: male gender [RR (95% CI) = 0.46 (0.21-0.99)], higher CD4 percentage [RR (95% CI) = 0.95 (0.90-1.00)], syphilis history [RR (95% CI) = 0.37 (0.13-1.04)], and higher total protein [RR (95% CI) = 0.70 (0.45-1.09)]. Adjustment for potential confounding by measured variables did not meaningfully change these results.
Cutaneous hypersensitivity reactions to cotrimoxazole in the setting of primary PCP prophylaxis are common. Although male gender, higher CD4 percentage, syphilis history, and higher total protein have at least borderline associations with these reactions, routinely collected clinical and laboratory variables do not appear to be sufficiently associated with the reactions to permit development of a clinically useful prediction rule.
测定在原发性卡氏肺孢子虫肺炎(PCP)预防治疗中,皮肤对复方新诺明过敏反应的发生率;测定严重反应的发生率;并确定这些结果的预测因素。
回顾性队列研究。
一家大学门诊HIV诊所和一家大学附属内科及传染病医疗实践机构。
236名接受复方新诺明进行原发性PCP预防治疗的HIV感染者。
无。
皮肤过敏反应的发生情况,定义为皮疹、发热或瘙痒,导致复方新诺明永久停用。严重反应定义为导致住院或使用皮质类固醇进行全身治疗的反应。采用Cox回归计算一系列临床和实验室变量的相对率(RRs)及95%置信区间(CIs)。
48名(20%)受试者出现皮肤过敏反应,其中6名(12.5%)为严重反应。在未校正分析中,以下因素显示至少有临界相关性:男性[RR(95%CI)=0.46(0.21 - 0.99)]、较高的CD4百分比[RR(95%CI)=0.95(0.90 - 1.00)]、梅毒病史[RR(95%CI)=0.37(0.13 - 1.04)]以及较高的总蛋白[RR(95%CI)=0.70(0.45 - 1.09)]。对测量变量的潜在混杂因素进行校正后,这些结果没有显著变化。
在原发性PCP预防治疗中,皮肤对复方新诺明的过敏反应很常见。虽然男性、较高的CD4百分比、梅毒病史和较高的总蛋白与这些反应至少有临界相关性,但常规收集的临床和实验室变量似乎与这些反应的关联程度不足以制定出临床有用的预测规则。